Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLYMPIA-3: Odronextamab + CHOP vs R-CHOP in previously untreated DLBCL
jRCT2041260115Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of odronextamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) in Part 1, Incidence of treatment-emergent adverse events (TEAEs) in Part 1 and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
odronextamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT2041260115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041260115.